The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).
 
Hui-Chuan Sun
Employment - Zhongshan Hospital, Fudan University
Honoraria - AstraZeneca; Bayer; BeiGene; Eisai; Hengrui Pharmaceutical; Innovent Biologics; MSD; Roche; TopAlliance BioSciences Inc; Zelgen
Research Funding - Innovent Biologics (Inst); MSD (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Radiomic features to predict tumor response to systemic therapy in liver cancer patients (Inst)
 
Xiao-Dong Zhu
Honoraria - Beigene; Eisai; Hengrui Pharmaceutical; Innovent Biologics; MSD; Roche
 
Kui Wang
No Relationships to Disclose
 
Ning Yang
No Relationships to Disclose
 
Yong-Jun Chen
No Relationships to Disclose
 
Ming Kuang
No Relationships to Disclose
 
Hui Xue
No Relationships to Disclose
 
Ying-Cheng Yang
No Relationships to Disclose
 
Feng Ye
No Relationships to Disclose
 
Shun-Li Shen
No Relationships to Disclose
 
Cheng Huang
No Relationships to Disclose
 
Yinghao Shen
No Relationships to Disclose
 
Jian Zhou
Consulting or Advisory Role - AstraZeneca; MSD
Research Funding - AstraZeneca; Innovent Biologics; Junshi Biosciences; MSD; Roche
 
Jia Fan
No Relationships to Disclose